(Q35034815)

5 August 2017

1 reference

title

Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia (English)

1 reference

5 August 2017

Francis J Giles

1

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Expert Review of Anticancer Therapy

5 August 2017

published in

1 reference

5 August 2017

volume

2

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

630-640

1 reference

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Antiangiogenic therapy in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Cell-specific regulation of apoptosis by designed enediynes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

New drugs in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

Myelodysplastic syndrome is not merely "preleukemia"

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.6.630

21 January 2018

Identifiers

DOI

10.1586/14737140.2.6.630

1 reference

5 August 2017

1 reference